{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:55:32Z","timestamp":1790916932728,"version":"4.1.0"},"reference-count":176,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The eye is one of the primary structures of the body that allows perception of the entire\nworld. A person\u2019s activities rely entirely on having good vision, and any diseases or problems encountered\nwith vision create a troublesome condition in life. Ocular delivery can potentially treat\nnumerous eye-related disease conditions. The diseases that affect the eyes include glaucoma, dry eye\nsyndrome, cataracts, conjunctivitis, diabetic retinopathy, keratitis, uveitis, Endophthalmitis, allergies,\nand others. The conventional dosage forms (eye drops, ointment) pose numerous challenges in treating\nocular infections owing to their complex nature and several barriers. Recent advances in artificial\nintelligence and machine learning provide a preliminary diagnosis in the early stages of disease identification\nand are also useful during retinal surgery. The poor ocular penetration, low bioavailability,\nshort retention time, and frequent administration are the limitations of conventional treatments. These\nlimitations are easily solved with nanotechnology-driven approaches. The current state-of-the-art\nreview explores eye physiology, barriers (precorneal, corneal epithelium, lacrimal sac, blood-ocular,\nand efflux protein), limitations of the conventional and nanotechnology-based delivery (Lipid-based,\npolymer-based, metal and inorganic NPs, vesicle-based NPs, and miscellaneous). These nanocarriers\nfacilitate good permeation, extended retention time, augment solubility, improve bioavailability,\nimprove patient comfort and compliance, and minimize dosage application. The nanocarriers are\nequally effective in treating the anterior and posterior regions of the eyes, whereas conventional ones\nhave failed to treat them effectively. The recently approved agents and patents are elaborated on ocular\ndrug delivery. Advancements in stem cell and gene therapy are also gaining attention for treating\ninherited and acquired retinal diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672018383855251007175252","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:00:20Z","timestamp":1761192020000},"page":"628-647","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-5906","authenticated-orcid":true,"given":"Abhishek","family":"Kanugo","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, SVKM NMIMS School of Pharmacy and Technology Management,Shirpur-425405, India"},{"name":"Department of Pharmaceutical Quality Assurance, School of Pharmacy and Technology Management,SVKM NMIMS Global University, Dhule-424001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikeeta","family":"Teli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, SVKM NMIMS School of Pharmacy and Technology Management,Shirpur-425405, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/pharmaceutics11070321","volume":"11","author":"Moiseev R.V.","year":"2019","unstructured":"Moiseev R.V.; Morrison P.W.J.; Steele F.; Khutoryanskiy V.V.; Penetration enhancers in ocular drug delivery. Pharmaceutics  2019,11(7),321","journal-title":"Pharmaceutics"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"15352","DOI":"10.3390\/ijms242015352","volume":"24","author":"Liu L.C.","year":"2023","unstructured":"Liu L.C.; Chen Y.H.; Lu D.W.; Overview of recent advances in nano-based ocular drug delivery. Int J Mol Sci  2023,24(20),15352","journal-title":"Int J Mol Sci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"120924","DOI":"10.1016\/j.ijpharm.2021.120924","volume":"607","author":"Mofidfar M.","year":"2021","unstructured":"Mofidfar M.; Abdi B.; Ahadian S.; Mostafavi E.; Desai T.A.; Abbasi F.; Sun Y.; Manche E.E.; Ta C.N.; Flowers C.W.; Drug delivery to the anterior segment of the eye: A review of current and future treatment strategies. Int J Pharm  2021,607,120924","journal-title":"Int J Pharm"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/pharmaceutics13081224","volume":"13","author":"Conrady C.D.","year":"2021","unstructured":"Conrady C.D.; Yeh S.; A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: The past, present, and future. Pharmaceutics  2021,13(8),1224","journal-title":"Pharmaceutics"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2024.05.031","volume":"371","author":"Ahmed B.","year":"2024","unstructured":"Ahmed B.; Jaiswal S.; Naryal S.; Shah R.M.; Alany R.G.; Kaur I.P.; In situ gelling systems for ocular drug delivery. J Control Release  2024,371,67-84","journal-title":"J Control Release"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"27835","DOI":"10.1039\/D0RA04971A","volume":"10","author":"Gorantla S.","year":"2020","unstructured":"Gorantla S.; Rapalli V.K.; Waghule T.; Singh P.P.; Dubey S.K.; Saha R.N.; Singhvi G.; Nanocarriers for ocular drug delivery: Current status and translational opportunity. RSC Advances  2020,10(46),27835-27855","journal-title":"RSC Advances"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1517\/17425247.1.1.99","volume":"1","author":"Raghava S.","year":"2004","unstructured":"Raghava S.; Hammond M.; Kompella U.B.; Periocular routes for retinal drug delivery. Expert Opin Drug Deliv  2004,1(1),99-114","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/24741264211028441","volume":"5","author":"Lam L.A.","year":"2021","unstructured":"Lam L.A.; Mehta S.; Lad E.M.; Emerson G.G.; Jumper J.M.; Awh C.C.; Intravitreal injection therapy: Current techniques and supplemental services. J Vitreoretin Dis  2021,5(5),438-447","journal-title":"J Vitreoretin Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","volume":"361","author":"Qi Q.","year":"2023","unstructured":"Qi Q.; Wei Y.; Zhang X.; Guan J.; Mao S.; Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery. J Control Release  2023,361,191-211","journal-title":"J Control Release"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4103\/ijo.IJO_1091_18","volume":"67","author":"Ram J.","year":"2019","unstructured":"Ram J.; Jinagal J.; Gupta P.C.; Pilania R.K.; Systemic toxicity of topical corticosteroids. Indian J Ophthalmol  2019,67(4),559-561","journal-title":"Indian J Ophthalmol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/myc.12822","volume":"61","author":"Mahmoudi S.","year":"2018","unstructured":"Mahmoudi S.; Masoomi A.; Ahmadikia K.; Tabatabaei S.A.; Soleimani M.; Rezaie S.; Ghahvechian H.; Banafsheafshan A.; Fungal keratitis: An overview of clinical and laboratory aspects. Mycoses  2018,61(12),916-930","journal-title":"Mycoses"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.survophthal.2023.09.004","volume":"69","author":"Putera I.","year":"2024","unstructured":"Putera I.; Ridwan A.S.; Dewi M.; Cifuentes-Gonz\u00e1lez C.; Rojas-Carabali W.; Sitompul R.; Edwar L.; Susiyanti M.; Aziza Y.; Pavesio C.; Chee S.P.; Mahendradas P.; Biswas J.; Kempen J.H.; Gupta V.; de-la-Torre A.; La Distia Nora R.; Agrawal R.; Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis. Surv Ophthalmol  2024,69(1),67-84","journal-title":"Surv Ophthalmol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"127207","DOI":"10.1016\/j.polymer.2024.127207","volume":"306","author":"Han J.","year":"2024","unstructured":"Han J.; Shu H.; Zhang L.; Huang S.; Latest advances in hydrogel therapy for ocular diseases. Polymer  2024,306,127207","journal-title":"Polymer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"103945","DOI":"10.1016\/j.jddst.2022.103945","volume":"78","author":"Kailasam V.","year":"2022","unstructured":"Kailasam V.; Cheruvu S.S.; Malani M.; Sai Kameswari S.M.; Kesharwani P.; Nirmal J.; Recent advances in novel formulation approaches for tacrolimus delivery in treatment of various ocular diseases. J Drug Deliv Sci Technol  2022,78,103945","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.jddst.2024.105785","volume":"97","author":"Chandel A.","year":"2024","unstructured":"Chandel A.; Kandav G.; Insights into ocular therapeutics: A comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery. J Drug Deliv Sci Technol  2024,97,105785","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"124899","DOI":"10.1016\/j.ijpharm.2024.124899","volume":"667","author":"Al Yabhouni S.A.","year":"2024","unstructured":"Al Yabhouni S.A.; Mozumder M.S.; Hassan N.; Mourad A.H.I.; Issa MD; , T.M.A.; Nanocarrier-Based, T.M.A. Nanocarrier-Based, ocular drug delivery: Challenges, prospects, and the therapeutic landscape in the United Arab Emirates. Int J Pharm  2024,667(Pt B),124899","journal-title":"Int J Pharm"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"114868","DOI":"10.1016\/j.addr.2023.114868","volume":"198","author":"Li L.","year":"2023","unstructured":"Li L.; Jia F.; Wang Y.; Liu J.; Tian Y.; Sun X.; Lei Y.; Ji J.; Trans-corneal drug delivery strategies in the treatment of ocular diseases. Adv Drug Deliv Rev  2023,198,114868","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1421959","DOI":"10.3389\/fmolb.2024.1421959","volume":"11","author":"Baig M.S.","year":"2024","unstructured":"Baig M.S.; Karade S.K.; Ahmad A.; Khan M.A.; Haque A.; Webster T.J.; Faiyazuddin M.; Al-Qahtani N.H.; Lipid-based nanoparticles: Innovations in ocular drug delivery. Front Mol Biosci  2024,11,1421959","journal-title":"Front Mol Biosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/20415990.2024.2346047","volume":"15","author":"Bisen A.C.","year":"2024","unstructured":"Bisen A.C.; Dubey A.; Agrawal S.; Biswas A.; Rawat K.S.; Srivastava S.; Bhatta R.S.; Recent updates on ocular disease management with ophthalmic ointments. Ther Deliv  2024,15(6),463-480","journal-title":"Ther Deliv"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3390\/molecules29102263","volume":"29","author":"Wu K.Y.","year":"2024","unstructured":"Wu K.Y.; Wang X.C.; Anderson M.; Tran S.D.; Advancements in nanosystems for ocular drug delivery: A focus on pediatric retinoblastoma. Molecules  2024,29(10),2263","journal-title":"Molecules"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"114293","DOI":"10.1016\/j.addr.2022.114293","volume":"186","author":"Mohammed Y.","year":"2022","unstructured":"Mohammed Y.; Holmes A.; Kwok P.C.L.; Kumeria T.; Namjoshi S.; Imran M.; Matteucci L.; Ali M.; Tai W.; Benson H.A.E.; Roberts M.S.; Advances and future perspectives in epithelial drug delivery. Adv Drug Deliv Rev  2022,186,114293","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","volume":"24","author":"Ahmed S.","year":"2023","unstructured":"Ahmed S.; Amin M.M.; Sayed S.; Ocular drug delivery: A comprehensive review. AAPS PharmSciTech  2023,24(2),66","journal-title":"AAPS PharmSciTech"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.drudis.2019.02.001","volume":"24","author":"Subrizi A.","year":"2019","unstructured":"Subrizi A.; del Amo E.M.; Korzhikov-Vlakh V.; Tennikova T.; Ruponen M.; Urtti A.; Design principles of ocular drug delivery systems: Importance of drug payload, release rate, and material properties. Drug Discov Today  2019,24(8),1446-1457","journal-title":"Drug Discov Today"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"Gote V.","year":"2019","unstructured":"Gote V.; Sikder S.; Sicotte J.; Pal D.; Ocular drug delivery: Present innovations and future challenges. J Pharmacol Exp Ther  2019,370(3),602-624","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3390\/pharmaceutics11090460","volume":"11","author":"Souto E.B.","year":"2019","unstructured":"Souto E.B.; Dias-Ferreira J.; L\u00f3pez-Machado A.; Ettcheto M.; Cano A.; Camins Espuny A.; Espina M.; Garcia M.L.; S\u00e1nchez-L\u00f3pez E.; Advanced formulation approaches for ocular drug delivery: State-Of-the-art and recent patents. Pharmaceutics  2019,11(9),460","journal-title":"Pharmaceutics"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3390\/pharmaceutics12060584","volume":"12","author":"Vicente-Pascual M.","year":"2020","unstructured":"Vicente-Pascual M.; G\u00f3mez-Aguado I.; Rodr\u00edguez-Castej\u00f3n J.; Rodr\u00edguez-Gasc\u00f3n A.; Muntoni E.; Battaglia L.; del Pozo-Rodr\u00edguez A.; Solin\u00eds Aspiazu M.\u00c1.; Topical administration of SLN-based gene therapy for the treatment of corneal inflammation by De Novo IL-10 production. Pharmaceutics  2020,12(6),584","journal-title":"Pharmaceutics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","volume":"13","author":"Kim H.M.","year":"2021","unstructured":"Kim H.M.; Woo S.J.; Ocular drug delivery to the retina: Current innovations and future perspectives. Pharmaceutics  2021,13(1),108","journal-title":"Pharmaceutics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.drudis.2021.02.027","volume":"26","author":"Gholizadeh S.","year":"2021","unstructured":"Gholizadeh S.; Wang Z.; Chen X.; Dana R.; Annabi N.; Advanced nanodelivery platforms for topical ophthalmic drug delivery. Drug Discov Today  2021,26(6),1437-1449","journal-title":"Drug Discov Today"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"102967","DOI":"10.1016\/j.redox.2023.102967","volume":"68","author":"B\u00f6hm E.W.","year":"2023","unstructured":"B\u00f6hm E.W.; Buonfiglio F.; Voigt A.M.; Bachmann P.; Safi T.; Pfeiffer N.; Gericke A.; Oxidative stress in the eye and its role in the pathophysiology of ocular diseases. Redox Biol  2023,68,102967","journal-title":"Redox Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/biomedicines11020292","volume":"11","author":"Dammak A.","year":"2023","unstructured":"Dammak A.; Pastrana C.; Martin-Gil A.; Carpena-Torres C.; Peral Cerda A.; Simovart M.; Alarma P.; Huete-Toral F.; Carracedo G.; Oxidative stress in the anterior ocular diseases: Diagnostic and treatment. Biomedicines  2023,11(2),292","journal-title":"Biomedicines"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.36000\/hbT.2022.06.002","volume":"6","author":"Bissell M.","year":"2022","unstructured":"Bissell M.; Fetian I.; Mozaffarieh M.; The role of oxidative stress in the pathogenesis of eye diseases. heakthbook TIMES  2022,6,72-77","journal-title":"heakthbook TIMES"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","volume":"64","author":"Li Y.","year":"2021","unstructured":"Li Y.; Yang G.; Zhang J.; Tang P.; Yang C.; Wang G.; Chen J.; Liu J.; Zhang L.; Ouyang L.; Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer. J Med Chem  2021,64(16),12022-12048","journal-title":"J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s11255-024-03990-1","volume":"56","author":"Rangaswamy D.","year":"2024","unstructured":"Rangaswamy D.; Nagaraju S.P.; Bhojaraja M.V.; Swaminathan S.M.; Prabhu R.A.; Rao I.R.; Shenoy S.V.; Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: An update. Int Urol Nephrol  2024,56(8),2635-2644","journal-title":"Int Urol Nephrol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/ph16081140","volume":"16","author":"Hang A.","year":"2023","unstructured":"Hang A.; Feldman S.; Amin A.P.; Ochoa J.A.R.; Park S.S.; Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders. Pharmaceuticals  2023,16(8),1140","journal-title":"Pharmaceuticals"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2403399","DOI":"10.1002\/advs.202403399","volume":"11","author":"Wu Y.","year":"2024","unstructured":"Wu Y.; Li X.; Fu X.; Huang X.; Zhang S.; Zhao N.; Ma X.; Saiding Q.; Yang M.; Tao W.; Zhou X.; Huang J.; Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases. Adv Sci  2024,11(32),2403399","journal-title":"Adv Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ophtha.2020.12.032","volume":"128","author":"Moore A.T.","year":"2021","unstructured":"Moore A.T.; Yu-Wai-Man P.; Mitochondrial disorders and the eye: A new era for diagnosis. Ophthalmology  2021,128(4),632-633","journal-title":"Ophthalmology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41433-023-02523-x","volume":"37","author":"Chen B.S.","year":"2023","unstructured":"Chen B.S.; Harvey J.P.; Gilhooley M.J.; Jurkute N.; Yu-Wai-Man P.; Mitochondria and the eye-manifestations of mitochondrial diseases and their management. Eye (Lond)  2023,37(12),2416-2425","journal-title":"Eye (Lond)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.3390\/ijms23084256","volume":"23","author":"Caban M.","year":"2022","unstructured":"Caban M.; Owczarek K.; Lewandowska U.; The role of metalloproteinases and their tissue inhibitors on ocular diseases: Focusing on potential mechanisms. Int J Mol Sci  2022,23(8),4256","journal-title":"Int J Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"108523","DOI":"10.1016\/j.exer.2021.108523","volume":"205","author":"Shoari A.","year":"2021","unstructured":"Shoari A.; Kanavi M.R.; Rasaee M.J.; Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; A review study. Exp Eye Res  2021,205,108523","journal-title":"Exp Eye Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"7752","DOI":"10.2174\/0109298673347323241119184648","volume":"32","author":"Kedar P.","year":"2025","unstructured":"Kedar P.; Bhattacharya S.; Kanugo A.; Prajapati B.G.; Novel strategies for the treatment of lung cancer: An in-depth analysis of the use of immunotherapy, precision medicine, and Artificial Intelligence to improve prognoses. Curr Med Chem  2025,32(35),7752-7776","journal-title":"Curr Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/bioengineering11020122","volume":"11","author":"Zhu Y.","year":"2024","unstructured":"Zhu Y.; Salowe R.; Chow C.; Li S.; Bastani O.; O\u2019Brien J.M.; Advancing glaucoma care: Integrating Artificial Intelligence in diagnosis, management, and progression detection. Bioengineering  2024,11(2),122","journal-title":"Bioengineering"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2024.04.009","volume":"70","author":"Waisberg E.","year":"2025","unstructured":"Waisberg E.; Ong J.; Kamran S.A.; Masalkhi M.; Paladugu P.; Zaman N.; Lee A.G.; Tavakkoli A.; Generative artificial intelligence in ophthalmology. Surv Ophthalmol  2025,70(1),1-11","journal-title":"Surv Ophthalmol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"104528","DOI":"10.1016\/j.pdpdt.2025.104528","volume":"52","author":"Tahmasebzadeh A.","year":"2025","unstructured":"Tahmasebzadeh A.; Sadeghi M.; Naseripour M.; Mirshahi R.; Ghaderi R.; Artificial intelligence and different image modalities in uveal melanoma diagnosis and prognosis: A narrative review. Photodiagn Photodyn Ther  2025,52,104528","journal-title":"Photodiagn Photodyn Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/app15041913","volume":"15","author":"Costin H.N.","year":"2025","unstructured":"Costin H.N.; Fira M.; Gora\u0219 L.; Artificial Intelligence in ophthalmology: Advantages and limits. Appl Sci  2025,15(4),1913","journal-title":"Appl Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3390\/medicina60040527","volume":"60","author":"Parmar U.P.S.","year":"2024","unstructured":"Parmar U.P.S.; Surico P.L.; Singh R.B.; Romano F.; Salati C.; Spadea L.; Musa M.; Gagliano C.; Mori T.; Zeppieri M.; Artificial Intelligence (AI) for early diagnosis of retinal diseases. Medicina  2024,60(4),527","journal-title":"Medicina"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1021\/acsbiomaterials.3c01144","volume":"10","author":"Azadi M.","year":"2024","unstructured":"Azadi M.; David A.E.; Enhancing ocular drug delivery: The effect of physicochemical properties of nanoparticles on the mechanism of their uptake by human cornea epithelial cells. ACS Biomater Sci Eng  2024,10(1),429-441","journal-title":"ACS Biomater Sci Eng"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","volume":"21","author":"Li S.","year":"2023","unstructured":"Li S.; Chen L.; Fu Y.; Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. J Nanobiotechnol  2023,21(1),232","journal-title":"J Nanobiotechnol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"114770","DOI":"10.1016\/j.addr.2023.114770","volume":"196","author":"Han H.","year":"2023","unstructured":"Han H.; Li S.; Xu M.; Zhong Y.; Fan W.; Xu J.; Zhou T.; Ji J.; Ye J.; Yao K.; Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. Adv Drug Deliv Rev  2023,196,114770","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","volume":"354","author":"Onugwu A.L.","year":"2023","unstructured":"Onugwu A.L.; Nwagwu C.S.; Onugwu O.S.; Echezona A.C.; Agbo C.P.; Ihim S.A.; Emeh P.; Nnamani P.O.; Attama A.A.; Khutoryanskiy V.V.; Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release  2023,354,465-488","journal-title":"J Control Release"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"850757","DOI":"10.3389\/fchem.2022.850757","volume":"10","author":"Razavi M.S.","year":"2022","unstructured":"Razavi M.S.; Ebrahimnejad P.; Fatahi Y.; D\u2019Emanuele A.; Dinarvand R.; Recent developments of nanostructures for the ocular delivery of natural compounds. Front Chem  2022,10,850757","journal-title":"Front Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/0113892010284407240212110745","volume":"25","author":"Sindhi K.","year":"2024","unstructured":"Sindhi K.; Kanugo A.; Recent developments in nanotechnology and immunotherapy for the diagnosis and treatment of pancreatic cancer. Curr Pharm Biotechnol  2024,25(2),143-168","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jconrel.2021.02.031","volume":"332","author":"Ghezzi M.","year":"2021","unstructured":"Ghezzi M.; Pescina S.; Padula C.; Santi P.; Del Favero E.; Cant\u00f9 L.; Nicoli S.; Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. J Control Release  2021,332,312-336","journal-title":"J Control Release"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","volume":"126","author":"Mandal A.","year":"2018","unstructured":"Mandal A.; Pal D.; Agrahari V.; Trinh H.M.; Joseph M.; Mitra A.K.; Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Adv Drug Deliv Rev  2018,126,67-95","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"11676","DOI":"10.1021\/acs.langmuir.1c01570","volume":"37","author":"McCauley P.J.","year":"2021","unstructured":"McCauley P.J.; Kumar S.; Calabrese M.A.; Criteria governing rod formation and growth in nonionic polymer micelles. Langmuir  2021,37(40),11676-11687","journal-title":"Langmuir"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/pharmaceutics15010205","volume":"15","author":"Shastri D.H.","year":"2023","unstructured":"Shastri D.H.; Silva A.C.; Almeida H.; Ocular delivery of therapeutic proteins: A review. Pharmaceutics  2023,15(1),205","journal-title":"Pharmaceutics"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/gels8020082","volume":"8","author":"Akhter M.H.","year":"2022","unstructured":"Akhter M.H.; Ahmad I.; Alshahrani M.Y.; Al-Harbi A.I.; Khalilullah H.; Afzal O.; Altamimi A.S.A.; Najib Ullah S.N.M.; Ojha A.; Karim S.; Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels  2022,8(2),82","journal-title":"Gels"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ph17040441","volume":"17","author":"Rusciano D.","year":"2024","unstructured":"Rusciano D.; Russo C.; The therapeutic trip of melatonin eye drops: From the ocular surface to the retina. Pharmaceuticals  2024,17(4),441","journal-title":"Pharmaceuticals"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/pharmaceutics12030253","volume":"12","author":"Terreni E.","year":"2020","unstructured":"Terreni E.; Chetoni P.; Tampucci S.; Burgalassi S.; Al-kinani A.; Alany R.; Monti D.; Assembling surfactants-mucoadhesive polymer nanomicelles (ASMP-Nano) for ocular delivery of cyclosporine-A. Pharmaceutics  2020,12(3),253","journal-title":"Pharmaceutics"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1208\/s12249-018-1267-x","volume":"20","author":"Mandal A.","year":"2019","unstructured":"Mandal A.; Patel P.; Pal D.; Mitra A.K.; Multi-layered nanomicelles as self-assembled nanocarrier systems for ocular peptide delivery. AAPS PharmSciTech  2019,20(2),66","journal-title":"AAPS PharmSciTech"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1049\/nbt2.12018","volume":"15","author":"Bose A.","year":"2021","unstructured":"Bose A.; Roy Burman D.; Sikdar B.; Patra P.; Nanomicelles: Types, properties and applications in drug delivery. IET Nanobiotechnol  2021,15(1),19-27","journal-title":"IET Nanobiotechnol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"105735","DOI":"10.1016\/j.ejps.2021.105735","volume":"159","author":"Mehra N.","year":"2021","unstructured":"Mehra N.; Aqil M.; Sultana Y.; A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and stability study. Eur J Pharm Sci  2021,159,105735","journal-title":"Eur J Pharm Sci"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010352026250213055117","volume":"26","author":"Mandan J.","year":"2025","unstructured":"Mandan J.; Kanugo D.A.; Recent Advancements in Nanoparticles-Based Approaches for the Theranostics of Glioblastoma Multiforme. Curr Pharm Biotechnol  In Press2025,26","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12951-023-01974-4","volume":"21","author":"Wei J.","year":"2023","unstructured":"Wei J.; Mu J.; Tang Y.; Qin D.; Duan J.; Wu A.; Next-generation nanomaterials: Advancing ocular anti-inflammatory drug therapy. J Nanobiotechnology  2023,21(1),282","journal-title":"J Nanobiotechnology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biomaterials.2017.02.016","volume":"125","author":"Soiberman U.","year":"2017","unstructured":"Soiberman U.; Kambhampati S.P.; Wu T.; Mishra M.K.; Oh Y.; Sharma R.; Wang J.; Al Towerki A.E.; Yiu S.; Stark W.J.; Kannan R.M.; Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation. Biomaterials  2017,125,38-53","journal-title":"Biomaterials"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.2174\/1389201023666211230113658","volume":"23","author":"Kanugo A.","year":"2022","unstructured":"Kanugo A.; Gautam R.K.; Kamal M.A.; Recent advances of nanotechnology in the diagnosis and therapy of triple- negative breast cancer (TNBC). Curr Pharm Biotechnol  2022,23(13),1581-1595","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2205754","DOI":"10.1002\/smll.202205754","volume":"19","author":"Kumar V.B.","year":"2023","unstructured":"Kumar V.B.; Sher I.; Rencus-Lazar S.; Rotenstreich Y.; Gazit E.; Functional carbon quantum dots for ocular imaging and therapeutic applications. Small  2023,19(7),2205754","journal-title":"Small"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12951-022-01362-4","volume":"20","author":"Zhao N.","year":"2022","unstructured":"Zhao N.; Gui X.; Fang Q.; Zhang R.; Zhu W.; Zhang H.; Li Q.; Zhou Y.; Zhao J.; Cui X.; Gao G.; Tang H.; Shen N.; Chen T.; Song H.; Shen W.; Graphene quantum dots rescue angiogenic retinopathy via blocking STAT3\/Periostin\/ERK signaling. J Nanobiotechnology  2022,20(1),174","journal-title":"J Nanobiotechnology"},{"key":"ref=68","first-page":"45","volume":"VI","author":"Kanugo A.","year":"2023","unstructured":"Kanugo A.; Recent advances of vesicles in drug delivery. Pharm Reson  2023,VI(I),45-60","journal-title":"Pharm Reson"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1872210516666220622115553","volume":"17","author":"Kanugo A.","year":"2023","unstructured":"Kanugo A.; Deshpande A.; Sharma R.; Formulation optimization and evaluation of nanocochleate gel of famciclovir for the treatment of Herpes Zoster. Recent Pat Nanotechnol  2023,17(3),259-269","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"103045","DOI":"10.1016\/j.jddst.2021.103045","volume":"67","author":"Tasharrofi N.","year":"2022","unstructured":"Tasharrofi N.; Nourozi M.; Marzban A.; How liposomes pave the way for ocular drug delivery after topical administration. J Drug Deliv Sci Technol  2022,67,103045","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"122616","DOI":"10.1016\/j.lfs.2024.122616","volume":"346","author":"Paramshetti S.","year":"2024","unstructured":"Paramshetti S.; Angolkar M.; Talath S.; Osmani R.A.M.; Spandana A.; Al Fatease A.; Hani U.; Ramesh K.V.R.N.S.; Singh E.; Unravelling the in vivo dynamics of liposomes: Insights into biodistribution and cellular membrane interactions. Life Sci  2024,346,122616","journal-title":"Life Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1089\/jop.2017.0099","volume":"34","author":"Altamirano-Vallejo J.C.","year":"2018","unstructured":"Altamirano-Vallejo J.C.; Navarro-Partida J.; Gonzalez-De la Rosa A.; Hsiao J.H.; Olgu\u00edn-Gutierrez J.S.; Gonzalez-Villegas A.C.; Keller B.C.; Bouzo-Lopez L.; Santos A.; Characterization and pharmacokinetics of triamcinolone acetonide-loaded liposomes topical formulations for vitreoretinal drug delivery. J Ocul Pharmacol Ther  2018,34(5),416-425","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"107198","DOI":"10.1016\/j.clay.2023.107198","volume":"247","author":"Zhao Y.","year":"2024","unstructured":"Zhao Y.; Hu J.; Ke Y.; Long Q.; Mao J.; Li H.; Xiao Z.; Pan K.; Yuan S.; Xue J.; Li W.; Zhong M.; Zang L.; Wei S.; Hou D.; Micro-interaction of montmorillonite-loaded nanoparticles with mucin promotes retention of betaxolol hydrochloride on the ocular surface and the tear film microenvironment. Appl Clay Sci  2024,247,107198","journal-title":"Appl Clay Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12951-019-0498-7","volume":"17","author":"Lai S.","year":"2019","unstructured":"Lai S.; Wei Y.; Wu Q.; Zhou K.; Liu T.; Zhang Y.; Jiang N.; Xiao W.; Chen J.; Liu Q.; Yu Y.; Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology  2019,17(1),64","journal-title":"J Nanobiotechnology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31288\/oftalmolzh202223741","volume":"97","author":"Mikheytseva I.M.","year":"2022","unstructured":"Mikheytseva I.M.; Grygorieva G.S.; Pasyechnikova N.V.; Kolomiichuk S.G.; Siroshtanenko T.I.; Konakhovych N.F.; Ocular hypotensive efficacy of a new liposomal latanoprost formulation administered by different routes for experimental ocular hypertension. Oftalmol Zh  2022,97(2),37-41","journal-title":"Oftalmol Zh"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"103780","DOI":"10.1016\/j.jddst.2022.103780","volume":"76","author":"Das B.","year":"2022","unstructured":"Das B.; Nayak A.K.; Mallick S.; Lipid-based nanocarriers for ocular drug delivery: An updated review. J Drug Deliv Sci Technol  2022,76,103780","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"119338","DOI":"10.1016\/j.ijpharm.2020.119338","volume":"583","author":"Fukushige K.","year":"2020","unstructured":"Fukushige K.; Tagami T.; Naito M.; Goto E.; Hirai S.; Hatayama N.; Yokota H.; Yasui T.; Baba Y.; Ozeki T.; Developing spray-freeze-dried particles containing a hyaluronic acid-coated liposome\u2013protamine\u2013DNA complex for pulmonary inhalation. Int J Pharm  2020,583,119338","journal-title":"Int J Pharm"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.35333\/jrp.2021.292","volume":"25","author":"Jindal S.","year":"2021","unstructured":"Jindal S.; Awasthi R.; Singare D.; Kulkarni G.T.; Preparation and in vitro evaluation of tacrolimus loaded liposomal vesicles by two methods: A comparative study. J ResPharm  2021,25,34-41","journal-title":"J ResPharm"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/pharmaceutics14050955","volume":"14","author":"Zingale E.","year":"2022","unstructured":"Zingale E.; Romeo A.; Rizzo S.; Cimino C.; Bonaccorso A.; Carbone C.; Musumeci T.; Pignatello R.; Fluorescent nanosystems for drug tracking and theranostics: Recent applications in the ocular field. Pharmaceutics  2022,14(5),955","journal-title":"Pharmaceutics"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"24513","DOI":"10.1371\/journal.pone.0024513","volume":"6","author":"Natarajan J.V.","year":"2011","unstructured":"Natarajan J.V.; Chattopadhyay S.; Ang M.; Darwitan A.; Foo S.; Zhen M.; Koo M.; Wong T.T.; Venkatraman S.S.; Sustained release of an anti-glaucoma drug: Demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One  2011,6(9),24513","journal-title":"PLoS One"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/17425247.2021.1872542","volume":"18","author":"L\u00f3pez-Cano J.J.","year":"2021","unstructured":"L\u00f3pez-Cano J.J.; Gonz\u00e1lez-Cela-Casamayor M.A.; Andr\u00e9s-Guerrero V.; Herrero-Vanrell R.; Molina-Mart\u00ednez I.T.; Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. Expert Opin Drug Deliv  2021,18(7),819-847","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1039\/C8TB03084G","volume":"7","author":"Vargas K.M.","year":"2019","unstructured":"Vargas K.M.; Shon Y.S.; Hybrid lipid\u2013nanoparticle complexes for biomedical applications. J Mater Chem B Mater Biol Med  2019,7(5),695-708","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10667857.2021.1873637","volume":"37","author":"Sharma S.","year":"2021","unstructured":"Sharma S.; Kanugo A.; Gaikwad J.; Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: A quality by design approach. Mater Technol  2021,37(8),1-10","journal-title":"Mater Technol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1872210517666221019102543","volume":"18","author":"Dugad T.","year":"2024","unstructured":"Dugad T.; Kanugo A.; Design optimization and evaluation of solid lipid nanoparticles of azelnidipine for the treatment of hypertension. Rec Pat Nanotechnol  2024,18(1),22-32","journal-title":"Rec Pat Nanotechnol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0118722105302631240816115638","volume":"18","author":"Shewale H.","year":"2024","unstructured":"Shewale H.; Kanugo A.; Formulation optimization and evaluation of patented solid lipid nanoparticles of ambrisentan for pulmonary arterial hypertension. Rec Pat Nanotechnol  2024,18,1-15","journal-title":"Rec Pat Nanotechnol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/0118722105284862240506045944","author":"Mulay L.","year":"2024","unstructured":"Mulay L.; Hegde N.; Kanugo A.; Formulation optimization and characterization of solid lipid nanoparticles of apixaban. Recent Pat Nanotechnol  2024,18","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.msec.2019.03.060","volume":"100","author":"Ahmad I.","year":"2019","unstructured":"Ahmad I.; Pandit J.; Sultana Y.; Mishra A.K.; Hazari P.P.; Aqil M.; Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater Sci Eng C  2019,100,959-970","journal-title":"Mater Sci Eng C"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.2147\/IJN.S190502","volume":"14","author":"Khames A.","year":"2019","unstructured":"Khames A.; Khaleel M.A.; El-Badawy M.F.; El-Nezhawy A.O.H.; Natamycin solid lipid nanoparticles \u2013 Sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: Preparation and optimization. Int J Nanomedicine  2019,14,2515-2531","journal-title":"Int J Nanomedicine"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/nano9010033","volume":"9","author":"Tatke A.","year":"2018","unstructured":"Tatke A.; Dudhipala N.; Janga K.Y.; Balguri S.P.; Avula B.; Jablonski M.M.; Majumdar S.; In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. Nanomaterials  2018,9(1),33","journal-title":"Nanomaterials"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s13346-020-00777-6","volume":"10","author":"Yadav M.","year":"2020","unstructured":"Yadav M.; Schiavone N.; Guzman-Aranguez A.; Giansanti F.; Papucci L.; Perez de Lara M.J.; Singh M.; Kaur I.P.; Correction to: Atorvastatin-loaded solid lipid nanoparticles as eye drops: Proposed treatment option for age-related macular degeneration (AMD). Drug Deliv Transl Res  2020,10(5),1531","journal-title":"Drug Deliv Transl Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"123667","DOI":"10.1016\/j.fuel.2022.123667","volume":"319","author":"Adil M.","year":"2022","unstructured":"Adil M.; Onaizi S.A.; Pickering nanoemulsions and their mechanisms in enhancing oil recovery: A comprehensive review. Fuel  2022,319,123667","journal-title":"Fuel"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1872210516666220623152440","author":"Sharma S.","year":"2022","unstructured":"Sharma S.; Kanugo A.; Kaur T.; Chaudhary D.; Formulation and characterization of self-microemulsifying drug delivery system (SMEDDS) of sertraline hydrochloride. Recent Pat Nanotechnol  2022,16","journal-title":"Recent Pat Nanotechnol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10311-020-01142-2","volume":"19","author":"Barradas T.N.","year":"2021","unstructured":"Barradas T.N.; Nanoemulsions of essential oils to improve solubility, stability and permeability: A review. Environ Chem Lett  2021,19,1153-1171","journal-title":"Environ Chem Lett"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1039\/D3NR03495J","volume":"16","author":"Roostaee M.","year":"2024","unstructured":"Roostaee M.; Derakhshani A.; Mirhosseini H.; Banaee Mofakham E.; Fathi-Karkan S.; Mirinejad S.; Sargazi S.; Barani M.; Composition, preparation methods, and applications of nanoniosomes as codelivery systems: A review of emerging therapies with emphasis on cancer. Nanoscale  2024,16(6),2713-2746","journal-title":"Nanoscale"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/nano10061191","volume":"10","author":"Durak S.","year":"2020","unstructured":"Durak S.; Esmaeili Rad M.; Alp Yetisgin A.; Eda Sutova H.; Kutlu O.; Cetinel S.; Zarrabi A.; Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials  2020,10(6),1191","journal-title":"Nanomaterials"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"118431","DOI":"10.1016\/j.ijpharm.2019.06.022","volume":"567","author":"Gugleva V.","year":"2019","unstructured":"Gugleva V.; Titeva S.; Rangelov S.; Momekova D.; Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system. Int J Pharm  2019,567,118431","journal-title":"Int J Pharm"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"102787","DOI":"10.1016\/j.jddst.2021.102787","volume":"66","author":"El-Haddad M.E.","year":"2021","unstructured":"El-Haddad M.E.; Hussien A.A.; Saeed H.M.; Farid R.M.; Down regulation of inflammatory cytokines by the bioactive resveratrol-loaded chitoniosomes in induced ocular inflammation model. J Drug Deliv Sci Technol  2021,66,102787","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"120380","DOI":"10.1016\/j.ijpharm.2021.120380","volume":"598","author":"Allam A.","year":"2021","unstructured":"Allam A.; Elsabahy M.; El Badry M.; Eleraky N.E.; Betaxolol\u2010loaded niosomes integrated within pH\u2010sensitive in situ forming gel for management of glaucoma. Int J Pharm  2021,598,120380","journal-title":"Int J Pharm"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/ph17040511","volume":"17","author":"Batur E.","year":"2024","unstructured":"Batur E.; \u00d6zdemir S.; Durgun M.E.; \u00d6zsoy Y.; Vesicular drug delivery systems: Promising approaches in ocular drug delivery. Pharmaceutics  2024,17(4),511","journal-title":"Pharmaceutics"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"123021","DOI":"10.1016\/j.ijpharm.2023.123021","volume":"640","author":"Uner B.","year":"2023","unstructured":"Uner B.; Ozdemir S.; Nur Pilevne S.; Cenk Celebi A.R.; Timolol-loaded ethosomes for ophthalmic delivery: Reduction of high intraocular pressure in vivo. Int J Pharm  2023,640,123021","journal-title":"Int J Pharm"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2200331","DOI":"10.1002\/adtp.202200331","volume":"6","author":"Sushma M.V.","year":"2023","unstructured":"Sushma M.V.; Sankaranarayanan S.A.; Bantal V.; Pemmaraju D.B.; Rengan A.K.; Ethosomal nanoformulations for combinational photothermal therapy of fungal keratitis. Adv Ther  2023,6(5),2200331","journal-title":"Adv Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/biomedicines11041114","volume":"11","author":"Sivadasan D.","year":"2023","unstructured":"Sivadasan D.; Sultan M.H.; Alqahtani S.S.; Javed S.; Cubosomes in drug delivery-A comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines  2023,11(4),1114","journal-title":"Biomedicines"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2683466","DOI":"10.1155\/2024\/2683466","volume":"2024","author":"Nath A.G.","year":"2024","unstructured":"Nath A.G.; Dubey P.; Kumar A.; Vaiphei K.K.; Rosenholm J.M.; Bansal K.K.; Gulbake A.; Recent advances in the use of cubosomes as drug carriers with special emphasis on topical applications. J Lipids  2024,2024(1),2683466","journal-title":"J Lipids"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/aps.2010.98","volume":"31","author":"Han S.","year":"2010","unstructured":"Han S.; Shen J.; Gan Y.; Geng H.; Zhang X.; Zhu C.; Gan L.; Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin  2010,31(8),990-998","journal-title":"Acta Pharmacol Sin"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7324\/JAPS.2016.60930","volume":"6","author":"Ali Z.","year":"2016","unstructured":"Ali Z.; Sharma P.; Warsi M.; Fabrication and evaluation of ketorolac loaded cubosome for ocular drug delivery. J Appl Pharm Sci  2016,6,204-208","journal-title":"J Appl Pharm Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jddst.2019.04.036","volume":"52","author":"Eldeeb A.E.","year":"2019","unstructured":"Eldeeb A.E.; Salah S.; Ghorab M.; Formulation and evaluation of cubosomes drug delivery system for treatment of glaucoma: Ex-vivo permeation and in-vivo pharmacodynamic study. J Drug Deliv Sci Technol  2019,52,236-247","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1208\/s12249-017-0763-8","volume":"18","author":"Huang J.","year":"2017","unstructured":"Huang J.; Peng T.; Li Y.; Zhan Z.; Zeng Y.; Huang Y.; Pan X.; Wu C.Y.; Wu C.; Ocular cubosome drug delivery system for timolol maleate: Preparation, characterization, cytotoxicity, ex vivo, and in vivo evaluation. AAPS PharmSciTech  2017,18(8),2919-2926","journal-title":"AAPS PharmSciTech"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"709","DOI":"10.5958\/0974-360X.2020.00135.3","volume":"13","author":"Rajani T.","year":"2020","unstructured":"Rajani T.; Mahesh G.; Reddy B.C.S.; Formulation and evaluation of dexamethasone loaded cubosomes. Res J Pharma Tech  2020,13(2),709-714","journal-title":"Res J Pharma Tech"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2162162","DOI":"10.1080\/10717544.2022.2162162","volume":"30","author":"Shoman N.A.","year":"2023","unstructured":"Shoman N.A.; Gebreel R.M.; El-Nabarawi M.A.; Attia A.; Optimization of hyaluronan-enriched cubosomes for bromfenac delivery enhancing corneal permeation: Characterization, ex vivo, and in vivo evaluation. Drug Deliv  2023,30(1),2162162","journal-title":"Drug Deliv"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1080\/10717544.2021.1989090","volume":"28","author":"Teba H.E.","year":"2021","unstructured":"Teba H.E.; Khalil I.A.; El Sorogy H.M.; Novel cubosome based system for ocular delivery of acetazolamide. Drug Deliv  2021,28(1),2177-2186","journal-title":"Drug Deliv"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4274\/tjps.galenos.2021.53533","volume":"19","author":"Ajrin M.","year":"2022","unstructured":"Ajrin M.; Anjum F.; Proniosome: A promising approach for vesicular drug delivery. Turk J Pharm Sci  2022,19(4),462-475","journal-title":"Turk J Pharm Sci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"119835","DOI":"10.1016\/j.ijpharm.2020.119835","volume":"589","author":"Aboali F.A.","year":"2020","unstructured":"Aboali F.A.; Habib D.A.; Elbedaiwy H.M.; Farid R.M.; Curcumin-loaded proniosomal gel as a biofreindly alternative for treatment of ocular inflammation: In-vitro and in-vivo assessment. Int J Pharm  2020,589,119835","journal-title":"Int J Pharm"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/pharmaceutics15041124","volume":"15","author":"Hendawy O.M.","year":"2023","unstructured":"Hendawy O.M.; Al-Sanea M.M.; Elbargisy R.M.; Rahman H.U.; Gomaa H.A.M.; Mohamed A.A.B.; Ibrahim M.F.; Kassem A.M.; Elmowafy M.; Development of olive oil containing phytosomal nanocomplex for improving skin delivery of quercetin: Formulation design optimization, in vitro and ex vivo appraisals. Pharmaceutics  2023,15(4),1124","journal-title":"Pharmaceutics"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"140","DOI":"10.21608\/rpbs.2023.219887.1238","volume":"7","author":"Gad S.","year":"2023","unstructured":"Gad S.; Hanna P.; Ibrahem H.; Mortagi Y.; Surfactants\u2019 role in nanovesicles drug delivery system. Rec Pharma Biomed Sci  2023,7(3),140-149","journal-title":"Rec Pharma Biomed Sci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/DDDT.S91730","volume":"10","author":"Salem H.","year":"2016","unstructured":"Salem H.; Ahmed S.M.; Omar M.M.; Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery. Drug Des Devel Ther  2016,10,277-295","journal-title":"Drug Des Devel Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"108151","DOI":"10.1016\/j.exer.2020.108151","volume":"198","author":"Apaolaza P.S.","year":"2020","unstructured":"Apaolaza P.S.; Busch M.; Asin-Prieto E.; Peynshaert K.; Rathod R.; Remaut K.; D\u00fcnker N.; G\u00f6pferich A.; Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution. Exp Eye Res  2020,198,108151","journal-title":"Exp Eye Res"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/opt4010007","volume":"4","author":"Kavalaraki A.","year":"2023","unstructured":"Kavalaraki A.; Spyratou E.; Kouri M.A.; Efstathopoulos E.P.; Gold nanoparticles as contrast agents in ophthalmic imaging. Optics  2023,4,74-99","journal-title":"Optics"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.biopha.2017.04.079","volume":"91","author":"Anbukkarasi M.","year":"2017","unstructured":"Anbukkarasi M.; Thomas P.A.; Sheu J.R.; Geraldine P.; In vitro antioxidant and anticataractogenic potential of silver nanoparticles biosynthesized using an ethanolic extract of Tabernaemontana divaricata leaves. Biomed Pharmacother  2017,91,467-475","journal-title":"Biomed Pharmacother"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.2147\/IJN.S406184","volume":"18","author":"Lu C.","year":"2023","unstructured":"Lu C.; Liu Y.; Liu Y.; Kou G.; Chen Y.; Wu X.; Lv Y.; Cai J.; Chen R.; Luo J.; Yang X.; Silver nanoparticles cause neural and vascular disruption by affecting key neuroactive ligand-receptor interaction and VEGF signaling pathways. Int J Nanomedicine  2023,18,2693-2706","journal-title":"Int J Nanomedicine"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/antiox7080097","volume":"7","author":"Dhall A.","year":"2018","unstructured":"Dhall A.; Self W.; Cerium oxide nanoparticles: A brief review of their synthesis methods and biomedical applications. Antioxidants  2018,7,97","journal-title":"Antioxidants"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.actbio.2024.07.003","volume":"185","author":"Zou H.","year":"2024","unstructured":"Zou H.; Hong Y.; Xu B.; Wang M.; Xie H.; Lin Q.; Multifunctional cerium oxide nanozymes with high ocular surface retention for dry eye disease treatment achieved by restoring redox balance. Acta Biomater  2024,185,441-455","journal-title":"Acta Biomater"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1039\/D1CS00659B","volume":"51","author":"Vallet-Reg\u00ed M.","year":"2022","unstructured":"Vallet-Reg\u00ed M.; Sch\u00fcth F.; Lozano D.; Colilla M.; Manzano M.; Engineering mesoporous silica nanoparticles for drug delivery: Where are we after two decades? Chem Soc Rev  2022,51(13),5365-5451","journal-title":"Chem Soc Rev"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1177\/0885328220977605","volume":"35","author":"Paiva M.R.B.","year":"2021","unstructured":"Paiva M.R.B.; Andrade G.F.; Dourado L.F.N.; Castro B.F.M.; Fialho S.L.; Sousa E.M.B.; Silva-Cunha A.; Surface functionalized mesoporous silica nanoparticles for intravitreal application of tacrolimus. J Biomater Appl  2021,35(8),1019-1033","journal-title":"J Biomater Appl"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/pharmaceutics15061597","volume":"15","author":"Al-Nimry S.S.","year":"2023","unstructured":"Al-Nimry S.S.; Daghmash R.M.; Three dimensional printing and its applications focusing on microneedles for drug delivery. Pharmaceutics  2023,15(6),1597","journal-title":"Pharmaceutics"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.37285\/ijpsn.2023.16.4.8","volume":"16","author":"Kanugo A.","year":"2023","unstructured":"Kanugo A.; Recent advancement of microneedle technique in diagnosis and therapy of diseases. Inter J Pharma Sci Nanotech  2023,16(4),6907-6920","journal-title":"Inter J Pharma Sci Nanotech"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13346-021-01032-2","volume":"12","author":"Albadr A.A.","year":"2022","unstructured":"Albadr A.A.; Tekko I.A.; Vora L.K.; Ali A.A.; Laverty G.; Donnelly R.F.; Thakur R.R.S.; Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections. Drug Deliv Transl Res  2022,12(4),931-943","journal-title":"Drug Deliv Transl Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"849","DOI":"10.16438\/J.0513-4870.2020-1436","author":"Li M.","year":"2021","unstructured":"Li M.; Yu X.; Jin Y.; Wu, Z Minimally Invasive Dissolving Microneedles for Ocular Brinzolamide Delivery. Yao Xue Xue Bao  2021,849-854","journal-title":"Yao Xue Xue Bao"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1021\/nn506599f","volume":"9","author":"Yuan X.","year":"2015","unstructured":"Yuan X.; Marcano D.C.; Shin C.S.; Hua X.; Isenhart L.C.; Pflugfelder S.C.; Acharya G.; Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano  2015,9(2),1749-1758","journal-title":"ACS Nano"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"41881","DOI":"10.1016\/j.heliyon.2025.e41881","volume":"11","author":"Tafti M.F.","year":"2025","unstructured":"Tafti M.F.; Fayyaz Z.; Aghamollaei H.; Jadidi K.; Faghihi S.; Drug delivery strategies to improve the treatment of corneal disorders. Heliyon  2025,11(2),41881","journal-title":"Heliyon"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.6b00488","volume":"13","author":"Marcano D.C.","year":"2016","unstructured":"Marcano D.C.; Shin C.S.; Lee B.; Isenhart L.C.; Liu X.; Li F.; Jester J.V.; Pflugfelder S.C.; Simpson J.; Acharya G.; Synergistic cysteamine delivery nanowafer as an efficacious treatment modality for corneal cystinosis. Mol Pharm  2016,13(10),3468-3477","journal-title":"Mol Pharm"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2015.07.007","volume":"213","author":"Coursey T.G.","year":"2015","unstructured":"Coursey T.G.; Henriksson J.T.; Marcano D.C.; Shin C.S.; Isenhart L.C.; Ahmed F.; De Paiva C.S.; Pflugfelder S.C.; Acharya G.; Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release  2015,213,168-174","journal-title":"J Control Release"},{"key":"ref=132","author":"De La P.","year":"2024","unstructured":"De La P.; D\u00edaz R.;  Conductive interpenetrated hydrogels for biomedical applications  2024","journal-title":"Conductive interpenetrated hydrogels for biomedical applications"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"112212","DOI":"10.1016\/j.msec.2021.112212","volume":"127","author":"Fang G.","year":"2021","unstructured":"Fang G.; Yang X.; Wang Q.; Zhang A.; Tang B.; Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. Mater Sci Eng C  2021,127,112212","journal-title":"Mater Sci Eng C"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/10717544.2011.595839","volume":"18","year":"2011","unstructured":"hui-hui, Z.; qiu-hua, L.; zhi-jun, Y.; wei-san, P.; shu-fang, N. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo. Drug Deliv  2011,18(7),502-510","journal-title":"Drug Deliv"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.actbio.2022.01.043","volume":"141","author":"Ross M.","year":"2022","unstructured":"Ross M.; Hicks E.A.; Rambarran T.; Sheardown H.; Thermo-sensitivity and erosion of chitosan crosslinked poly[N-isopropylacrylamide-co-(acrylic acid)-co-(methyl methacrylate)] hydrogels for application to the inferior fornix. Acta Biomater  2022,141,151-163","journal-title":"Acta Biomater"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"138979","DOI":"10.1016\/j.ijbiomac.2024.138979","volume":"290","author":"Biswal S.","year":"2025","unstructured":"Biswal S.; Parmanik A.; Das D.; Sahoo R.N.; Nayak A.K.; Gellan gum-based in-situ gel formulations for ocular drug delivery: A practical approach. Int J Biol Macromol  2025,290,138979","journal-title":"Int J Biol Macromol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1021\/acs.biomac.3c00532","volume":"24","author":"Mart\u00ednez G.","year":"2023","unstructured":"Mart\u00ednez G.; Begines B.; Pajuelo E.; V\u00e1zquez J.; Rodriguez-Albelo L.M.; Cofini D.; Torres Y.; Alcudia A.; Versatile biodegradable Poly(acrylic acid)-Based hydrogels infiltrated in porous titanium implants to improve the biofunctional performance. Biomacromolecules  2023,24(11),4743-4758","journal-title":"Biomacromolecules"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.fhfh.2022.100071","volume":"2","author":"Karmakar S.","year":"2022","unstructured":"Karmakar S.; Manna S.; Kabiraj S.; Jana S.; Recent progress in alginate-based carriers for ocular targeting of therapeutics. Food Hydrocoll Health  2022,2,100071","journal-title":"Food Hydrocoll Health"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4103\/IJO.IJO_17_23","volume":"71","author":"Sah R.","year":"2023","unstructured":"Sah R.; Sharma N.; Priyadarshini K.; Titiyal J.S.; Contact lenses for the treatment of ocular surface diseases. Indian J Ophthalmol  2023,71(4),1135-1141","journal-title":"Indian J Ophthalmol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4103\/IJO.IJO_2778_22","volume":"71","author":"Chaudhary S.","year":"2023","unstructured":"Chaudhary S.; Ghimire D.; Basu S.; Agrawal V.; Jacobs D.S.; Shanbhag S.S.; Contact lenses in dry eye disease and associated ocular surface disorders. Indian J Ophthalmol  2023,71(4),1142-1153","journal-title":"Indian J Ophthalmol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.3390\/molecules26185577","volume":"26","author":"Rykowska I.","year":"2021","unstructured":"Rykowska I.; Nowak I.; Nowak R.; Soft contact lenses as drug delivery systems: A review. Molecules  2021,26(18),5577","journal-title":"Molecules"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3109\/10717544.2016.1138342","volume":"23","author":"Maulvi F.A.","year":"2016","unstructured":"Maulvi F.A.; Soni T.G.; Shah D.O.; A review on therapeutic contact lenses for ocular drug delivery. Drug Deliv  2016,23(8),3017-3026","journal-title":"Drug Deliv"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1167\/iovs.11-8215","volume":"53","author":"Garhwal R.","year":"2012","unstructured":"Garhwal R.; Shady S.F.; Ellis E.J.; Ellis J.Y.; Leahy C.D.; McCarthy S.P.; Crawford K.S.; Gaines P.; Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials. Invest Ophthalmol Vis Sci  2012,53(3),1341-1352","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"102413","DOI":"10.1016\/j.jddst.2021.102413","volume":"63","author":"Wuchte L.D.","year":"2021","unstructured":"Wuchte L.D.; DiPasquale S.A.; Byrne M.E.; In vivo drug delivery via contact lenses: The current state of the field from origins to present. J Drug Deliv Sci Technol  2021,63,102413","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/ma11071125","volume":"11","author":"Choi S.W.","year":"2018","unstructured":"Choi S.W.; Kim J.; Therapeutic contact lenses with polymeric vehicles for ocular drug delivery: A review. Materials  2018,11(7),1125","journal-title":"Materials"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"105503","DOI":"10.1016\/j.ejps.2020.105503","volume":"154","author":"Torres-Luna C.","year":"2020","unstructured":"Torres-Luna C.; Fan X.; Domszy R.; Hu N.; Wang N.S.; Yang A.; Hydrogel-based ocular drug delivery systems for hydrophobic drugs. Eur J Pharm Sci  2020,154,105503","journal-title":"Eur J Pharm Sci"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jconrel.2023.07.036","volume":"360","author":"Sun R.","year":"2023","unstructured":"Sun R.; Ma S.; Chen X.; Deng Y.; Gou J.; Yin T.; He H.; Wang Y.; Tang X.; Zhang Y.; Inflammation-responsive molecular-gated contact lens for the treatment of corneal neovascularization. J Control Release  2023,360,818-830","journal-title":"J Control Release"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12015-025-10884-x","volume":"2025","author":"Chen K.Y.","year":"2025","unstructured":"Chen K.Y.; Chan H.C.; Chan C.M.; Can stem cell therapy revolutionize ocular disease treatment? A critical review of preclinical and clinical advances. Stem Cell Rev Rep  2025,2025,1-26","journal-title":"Stem Cell Rev Rep"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12951-025-03095-6","volume":"23","author":"Tang Z.","year":"2025","unstructured":"Tang Z.; Ye F.; Ni N.; Fan X.; Lu L.; Gu P.; Frontier applications of retinal nanomedicine: Progress, challenges and perspectives. J Nanobiotechnology  2025,23(1),143","journal-title":"J Nanobiotechnology"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"103823","DOI":"10.1016\/j.htct.2025.103823","volume":"47","author":"Kim C.","year":"2025","unstructured":"Kim C.; Serapicos P.C.Z.; Lustosa C.M.; Ibanez A.S.S.; Zecchin V.G.; de Oliveira L.A.; Ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in a pediatric population. Hematol Transfus Cell Ther  2025,47(2),103823","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref=151","year":"2024","unstructured":"Clinical trials.  Available from:  https:\/\/www.fightingblindness.ca\/clinical-trials\/2024"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"102008","DOI":"10.1016\/j.mcp.2025.102008","volume":"79","author":"Szab\u00f3 V.","year":"2025","unstructured":"Szab\u00f3 V.; Vars\u00e1nyi B.; Barboni M.; Tak\u00e1cs \u00c1.; Kn\u00e9zy K.; Moln\u00e1r M.J.; Nagy Z.Z.; Gy\u00f6rgy B.; Rivolta C.; Insights into eye genetics and recent advances in ocular gene therapy. Mol Cell Probes  2025,79,102008","journal-title":"Mol Cell Probes"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"112265","DOI":"10.1016\/j.isci.2025.112265","volume":"28","author":"Liu Z.","year":"2025","unstructured":"Liu Z.; Zhang H.; Jia H.; Wang H.; Huang Z.; Tang Y.; Wang Z.; Hu J.; Zhao X.; Li T.; Sun X.; The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis. iScience  2025,28(4),112265","journal-title":"iScience"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines13020365","volume":"13","author":"Kharisova C.B.","year":"2025","unstructured":"Kharisova C.B.; Kitaeva K.V.; Solovyeva V.V.; Sufianov A.A.; Sufianova G.Z.; Akhmetshin R.F.; Bulgar S.N.; Rizvanov A.A.; Looking to the future of viral vectors in ocular gene therapy: Clinical review. Biomedicines  2025,13(2),365","journal-title":"Biomedicines"},{"key":"ref=155","year":"2025","unstructured":"FDA approves encapsulated cell therapy for degenerative eye disease.   Available from:  https:\/\/www.asgct.org\/publications\/news\/march-2025\/encelto-cell-therapy-degenerative-eye-disease2025"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"104359","DOI":"10.1016\/j.drudis.2025.104359","volume":"30","author":"Aghajanpour S.","year":"2025","unstructured":"Aghajanpour S.; Amiriara H.; Ebrahimnejad P.; Slavcev R.A.; Advancing ocular gene therapy: A machine learning approach to enhance delivery, uptake and gene expression. Drug Discov Today  2025,30(5),104359","journal-title":"Drug Discov Today"},{"key":"ref=157","year":"2014","unstructured":"Stable liposomal formulations for ocular drug delivery. US Patent 20150190359A1  2014","journal-title":"US Patent 20150190359A1"},{"key":"ref=158","year":"2017","unstructured":"Subconjunctivaled depot formulating formulations for the eye medicine dispensing. EP Patent 3445335A4  2017","journal-title":"EP Patent 3445335A4"},{"key":"ref=159","year":"2017","unstructured":"Subconjunctival depot forming formulations for ocular drug delivery. US Patent 20190133931A1  2017","journal-title":"US Patent 20190133931A1"},{"key":"ref=160","year":"2016","unstructured":"Glycosaminoglycan-coated metallic nanoparticles and uses thereof. WO Patent 2016156788A1  2016","journal-title":"WO Patent 2016156788A1"},{"key":"ref=161","year":"2015","unstructured":"Ophthalmic nanoemulsion composition containing cyclosporine and method for preparing same. PH Patent 12015502587B1  2015","journal-title":"PH Patent 12015502587B1"},{"key":"ref=162","year":"2013","unstructured":"Cyclosporine-containing non-irritative nanoemulsion ophthalmic composition. US Patent 9320801B2  2013","journal-title":"US Patent 9320801B2"},{"key":"ref=163","year":"2013","unstructured":"Pharmaceutical nanoparticles showing improved mucosal transport. AU Patent 2013256092B2  2013","journal-title":"AU Patent 2013256092B2"},{"key":"ref=164","year":"2016","unstructured":"Non-irritant ophthalmic composition containing cyclosporin, and convenient preparation method. US Patent 20180214510A1  2016","journal-title":"US Patent 20180214510A1"},{"key":"ref=165","year":"2010","unstructured":"Pentablock Polymers. US Patent 20110250283A1  2010","journal-title":"US Patent 20110250283A1"},{"key":"ref=166","year":"2016","unstructured":"Determination of a service description most closely matching a specified service name. US Patent 20160224567A1  2016","journal-title":"US Patent 20160224567A1"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","volume":"191","author":"Nagai N.","year":"2022","unstructured":"Nagai N.; Otake H.; Novel drug delivery systems for the management of dry eye. Adv Drug Deliv Rev  2022,191,114582","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"104387","DOI":"10.1016\/j.jddst.2023.104387","volume":"83","author":"Khopade A.J.","year":"2023","unstructured":"Khopade A.J.; Halder A.; Patel V.; Shah H.; Shah A.; Burade V.; Zalawadia R.; Patel A.; Low dose ophthalmic solution of difluprednate for the management of pain and inflammation. J Drug Deliv Sci Technol  2023,83,104387","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"123449","DOI":"10.1016\/j.ijpharm.2023.123449","volume":"646","author":"Siriwardane D.A.","year":"2023","unstructured":"Siriwardane D.A.; Jiang W.; Mudalige T.; Profiling in-vitro release of verteporfin from VISUDYNE\u00ae liposomal formulation and investigating verteporfin binding to human serum albumin. Int J Pharm  2023,646,123449","journal-title":"Int J Pharm"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"124151","DOI":"10.1016\/j.ijpharm.2024.124151","volume":"657","author":"Zhong C.","year":"2024","unstructured":"Zhong C.; Shi Z.; Binzel D.W.; Jin K.; Li X.; Guo P.; Li S.K.; Posterior eye delivery of angiogenesis-inhibiting RNA nanoparticles via subconjunctival injection. Int J Pharm  2024,657,124151","journal-title":"Int J Pharm"},{"key":"ref=171","year":"2021","unstructured":"TLC399 (ProDex) in subjects with macular edema due to retinal vein occlusion (RVO); NCT03093701  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT030937012021","journal-title":"NCT03093701"},{"key":"ref=172","year":"2020","unstructured":"POLAT-001 compared to latanoprost ophthalmic solution in patients with ocular hypertension and open-angle glaucoma; NCT02466399  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT024663992020","journal-title":"NCT02466399"},{"key":"ref=173","year":"2018","unstructured":"SYSTANE\u00ae family - Meibomian deficiency; NCT01733745  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT017337452018","journal-title":"NCT01733745"},{"key":"ref=174","year":"2024","unstructured":"CEQUA for Sj\u00f6gren\u2019s syndrome dry eye; NCT04835623.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT048356232024"},{"key":"ref=175","year":"2016","unstructured":"A randomized controlled trial comparing urea-loaded nanoparticles to placebo: a new concept for cataract management; NCT03001466.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT030014662016"},{"key":"ref=176","year":"2020","unstructured":"Safety and efficacy of KPI-121 in subjects with postsurgical inflammation and pain; NCT02793817.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT027938172020"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018383855251007175252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/246302\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018383855251007175252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:35:51Z","timestamp":1790915751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/246302\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":176,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018383855251007175252","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}